

PREFERRED DRUG LIST MEETING SCHEDULE

**State of Montana
Department of Public Health &
Human Services**

Montana Medicaid Drug Use Review (DUR) Board/Formulary Committee Meeting

The State of Montana Medicaid DUR Board/Formulary Committee will hold a meeting on :

Date: March 27, 2013 (Wednesday)
Time: 1:00 pm – 5:00 pm Mountain Time
Location: Best Western Great Northern Hotel
835 Great Northern Blvd, Helena

At this time the Montana Medicaid DUR Board/Formulary Committee will review the following drug classes for Preferred Drug List (PDL) review:

All drugs reviewed pertain to oral drugs unless otherwise indicated

NI- New information, ND- New Drug, NG-New Generic

The Department will review **GROUP 1** as **NEW** information is known to exist:

- ALZHEIMER'S AGENTS – new strength Exelon patch, NI - Razadyne/ER, Namenda
- ANTICONVULSANTS ND-Potiga, Oxtellar ER
- ANTIEMETICS - Emend
- ANTIPARKINSONS AGENTS (non-ergotamine dopamine agonists) – Neupro patch reintroduced, NG-ropinirole ER
- INCRETIN ENHANCERS/MIMETICS – ND-Kazano, Nesina, Oseni NI -Victoza, Tradjenta
- LIPOTROPICS, OTHERS (TGLA & NIACINS) – ND-Juxtapid, Vascepa, NI for class
- MULTIPLE SCLEROSIS AGENTS – ND Aubagio, NI – Ampyra, Gilenya,
- PAH AGENTS, ORAL & INHALATION – NI- Revatio, Letairis, NG sildenafil
- PANCREATIC ENZYMES ND-Ultresa, Viokace , Pertzeye
- ULCERATIVE COLITIS AGENTS – ND-Giazo, Uceris, Delzicol

The Department proposes no changes to the Formulary Committee's clinical recommendations to **GROUP 2** unless manufacturers submit **NEW** information:

- ANGIOTENSIN MODULATORS (ARBS)
- ANGIOTENSIN MODULATORS (ACE & DRI)
- ANGIOTENSIN MODULATORS COMBINATIONS
- ANTIHYPERTENSIVES, SYMPATHOLYTICS
- BETA BLOCKERS & COMBOS
- CALCIUM CHANNEL BLOCKERS
- INSULINS
- LIPOTROPICS, STATINS
- MEGLITINIDES
- PROTON PUMP INHIBITORS

The Department proposes no changes to **GROUP 3** as all available chemical entities are preferred :

- ALPHA-GLUCOSIDASE INHIBITORS
- SULFONYLUREAS-2ND GENERATION

Public Testimony will be taken into consideration in the committee's recommendations as to which drugs should be given preferred status in the above listed classes of medications for the state's Medicaid program. Sign-up for public comment will occur between 12:30pm -12:55 pm outside the Conference Room. See the General Procedures for Public Comment section of this document for further details.

Clinical Information: New clinical information (in electronic format in PDF in the AMCP style dossier or desired style) may be sent by e-mail on the drug classes listed above by March 12, 2013 to:

dcampana@mt.gov and pdl@mt.gov

Note: If you wish to submit clinical information pertaining to the PDL review process for drugs within the designated classes, peer-reviewed literature including off label peer-reviewed studies or AMCP style – dossiers will be accepted in electronic PDF format

only. Please note that all information sent is subject to public disclosure and that proprietary and confidential material should not be sent and that the sender accepts responsibility for all information sent. All information sent will be posted on a public website for viewing. Department Personnel will not sign manufacturer release of information waivers.

Montana Medicaid
Department of Public Health and Human Services
DUR Board/Formulary Committee Meeting
General Procedures for Public Comment

1. Thirty minutes prior to the beginning of the DUR Board Meeting, a sign up sheet for Public Comment will be posted for Pharmaceutical Manufacturers and Special Interest Groups for each Drug Class to be reviewed.
2. Sign up will close 5 minutes prior to the beginning of the DUR Board Meeting.
3. Speakers will be assigned on a first come basis respective to each Drug Class discussion.
4. Speakers will be asked to present NEW INFORMATION ONLY on their corresponding product or interest.
 - a. New Information is considered the following: new product in the drug class, new indication since the last review or new studies published since the last review, excluding placebo only studies. New studies must be submitted in electronic format no later than two weeks prior to the scheduled meeting.
 - b. Public comment will be allowed for up to 5 minutes to present new information about their product. However, please be respectful of your other colleagues and also of the Board's time. Please do not take 5 minutes if it is not needed. The DUR Board Coordinator has the option to end a speaker's comment time if the information is not relevant to the topic of discussion.
 - c. Speakers must state their name, their affiliation, and whom they are speaking on behalf of or on request of, with any funding or payment agreements disclosed. Any studies cited during the presentation should be referenced with the primary source of funding included.
 - d. Handouts are limited to two (2) pages (paper size: 8.5" by 11", one side only) of documentation. Access to computers or other technology presentation devices for slide presentations will not be available during this comment period.
 - e. Public Comment will be limited to clinical and social comments; pricing or financial information regarding products and outcomes will not be permissible. The Board will be utilizing clinical information only. Information regarding pricing, cost or any other information of a financial nature will not be permissible and should not be discussed in handouts or during presentation by any public speaker.
 - f. The speakers presenting handouts are asked to provide at least thirty (30) copies that will be distributed by Foundation staff to the DUR Board members, State staff and for public distribution.
 - g. Copies will be collected by Foundation staff members at the time of sign-up.
 - h. The State, MMA and the DUR Board will be allowed to ask questions if needed during the presentation or after for clarification or discussion. Presenters will only be allowed to answer questions when specifically requested to do so by the Board during the remainder of the meeting.
 - i. It is not permissible for presenters to interject or ask questions to DUR Board members during the session.
5. Individual products may only be represented by one presentation. For example, a product jointly ventured by two pharmaceutical companies can only be represented once.

Note: These procedures may be revised at the discretion of the Department.